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Although salicylates are widely used as antipyretic agents, the mechanism by
which they lower body temperature is controversial. It has been suggested that
these compounds act at peripheral sites of inflammation, by suppressing release
of endogenous pyrogen from leucocytes exposed to an inflammatory stimulus (1),
or by suppressing synthesis and release of fever-inducing prostaglandins (2, 3).
Alternatively, considerable evidence in both man (4) and rabbits (5, 6) indicates
that salicylates act centrally to lower fever by blocking the action of endogenous
pyrogen on certain temperature-sensitive hypothalamic neurons. For example,
stable fevers induced by infusions of leucocyte (endogenous) pyrogen in humans
persisted for 50 min or so after the infusion was discontinued (4). However, when
sodium salicylate was injected intravenously during the continuous pyrogen infu-
sion, temperature fell promptly. This rapid antipyretic effect of salicylate is best
explained by a central action rather than by altered production or release of pyro-
gen from the host's leucocytes.
This postulated central action clearly does not exclude the possibility that these
agents have peripheral antipyretic effects, as reported (1, 6). It seemed appro-
priate, therefore, to re-examine the action of salicylate on release of pyrogenic
agents from leucocytes, with a model which approximates conditions of in vivo
inflammation. The studies to be reported here indicate that salicylate does not sup-
press the release of pyrogen from human blood leucocytes following exposure to
endotoxin or a phagocytic stimulus in vitro. By contrast, as expected, salicylate
administered to rabbits suppressed fever to intravenous injection of endogenous
pyrogen.
MATERIAL AND METHODS
All glassware and buffers were made sterile and pyrogen-free by heating at
1600C for 2 hr or by autoclaving for 1.5 hr. Na salicylate U.S.P. (Mallinckrodt)
was dissolved in sterile pyrogen-free saline to 10 mg/ml, filtered through a Swinnex
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millipore filter, and stored at 40C. For infusion experiments, 100 mg/ml Na
salicylate solution was prepared. One-gram amounts were injected intravenously
into rabbits to test for possible endotoxin contamination. Human blood leucocytes
were prepared by methods described previously (7). Briefly, heparinized venous
blood was drawn from normal volunteers, separated by dextran sedimentation, and
the leucocytes suspended in modified Krebs-Ringer phosphate buffer pH 7.4 with
10 units heparin/ml. Incubation flasks contained 5-7.5 ml of 15% autologous
serum-KRP buffer with 1 X 107 leucocytes per ml, glucose 150 mg% and penicil-
lin 6000 units. Salicylate 40 mg% was incubated with leucocytes for one hour
before addition of bacteria. Heat-killed Staphylococcus albus, prepared as de-
scribed previously (7) was used at a ratio of 5-40 bacteria per leucocyte. In experi-
ments with endotoxin, a 1:10 dilution in saline of typhoid vaccine (Monovalent
Reference Std NRV-LS # 1, Walter Reed, Washington, D.C.) was filtered just
before use through a Swinnex millipore filter, and 0.3-0.5 ml/ 3 X 107 leucocytes
was used. Salicylate was added to leucocytes 1 hr after the endotoxin. Flasks were
incubated with shaking on a Dubnoff incubator at 370C for several hours, and
then placed in a stationary incubator at 370C overnight. In initial experiments with
bacteria, phagocytosis was confirmed by examination of coverslip smears two hours
after addition of staphylococci.
After incubation, flask contents were centrifuged at 2000g for 30 min, an aliquot
of the supematant was cultured in thioglycollate broth to confirm sterility, and
the remainder was injected at once or stored at 40C. for 1-5 days. Pyrogen release
was determined by assay in rabbits as described previously (8). AT represents the
maximum height of fever above pre-injection baseline temperature, occurring
within 75 min after injection. In some experiments, rabbit temperatures were con-
tinuously monitored on a Rustrak recorder. In all experiments, the same rabbits
received aliquots of supernatants from control and experimental preparations. Re-
sults of pyrogen assay of supernatants, reported in Tables 1 and 2, were tested
for significant differences by means of t-test for paired samples, using responses
of the same rabbit to a control and experimental supernatant as one pair. Super-
natant from leucocytes incubated without salicylate or activators was determined
to give an average temperature rise of less than 0.20C. in all instances.
Rabbit endogenous pyrogen (EP) was prepared as follows. One-hundred and
twenty ml. heparinized rabbit blood was centrifuged at 600g, the cells were resus-
pended in 25 ml plasma, and heparinized KRP buffer containing 150 mg% glucose
and 6000 units of penicillin was added to a final volume of 150 ml. Heat-killed
staphylococci (1.5 X 1010) were added, and the mixture was shaken gently at 370C
overnight. After centrifugation at 2000g for 30 min, the supematant containing
EP was removed, an aliquot cultured and assayed for pyrogenicity, and the re-
mainder stored at 40C.
Na salicylate for intraperitoneal injection was diluted to 20 mg/ml in KRP
buffer, and injected slowly through a blunt infusion needle to provide 250 mg/kg,
the dose used by others (1).
RESULTS
The results of experiments designed to investigate the effect of salicylate on pyro-
gen release from human blood cells in vitro are shown in Tables 1 and 2. Pre-incu-
bation of leucocytes with a high concentration of sodium salicylate (40 mg% )
did not alter the subsequent release of pyrogen after stimulation by phagocytosis
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TABLE 1
EFFECT OF Na SALICYLATE ON PYROGEN RELEASE in vitro FROM
LEUCOCYTES STIMULATED BY PHAGOCYTOSIS
Average AT(C) Bacteria
No. cells per
recipients per dose + Salicylate - Salicylate WBC
6 1.3 X 107 .54 ± .07a .62 ± .06 40:1
(1.2-1 .4)b
8 2.5 X 107 .75 ± .07 .86 ± .05 5:1
(2.1-3.2)
6 5 X 106 .48 ± .08 .44 ± .07 5:1
a SEM.
b Range.
TABLE 2
EFFECT OF Na SALICYLATE ON PYROGEN RELEASE in vitro FROM
LEUCOCYTES STIMULATED BY ENDOTOXIN
No. Average cells AT(0C
recipients per dose + Salicylate - Salicylate
8 2.3 X 107 .57 ± .08b .45 ± .07
(2.2-2.4 X 107)a
a Range.
b SEM.
(Table 1) (all p values >.05). Varying the numbers of leucocytes or the ratios
of bacteria to leucocytes did not change the results. Addition of salicylate to leuco-
cytes stimulated by endotoxin also did not suppress pyrogen release (Table 2).
In fact, in the presence of salicylate, this small dose of endotoxin caused somewhat
greater release of pyrogen p = <.02).
A more sensitive, quantitative assay for pyrogen was also carried out in several
of these experiments by injecting both a standard pyrogenic dose of each super-
natant and one half of this dose. Amounts were adjusted so that the average height
of fever for one aliquot of supernatant was about 0.60C and was proportionately
decreased by injection of half that amount (for example, see Fig. 1). It could then
be assumed that the dose-response curve was in its most sensitive range.' As shown
in Fig. 1, using this technique, again no difference could be detected in the amounts
of pyrogen present in supernatants derived from the same number of leucocytes
incubated with or without salicylate and bacteria. Similar results were obtained
in experiments with endotoxin. These findings, then, do not provide evidence for
a direct action of sodium salicylate on endogenous pyrogen release by human blood
leucocytes in vitro.
In order to confirm the central antipyretic action of salicylate, the following ex-
periment was done. Five rabbits received 1- and 0.5-ml aliquots of a preparation
of rabbit EP (see METHODS); the average temperature responses are shown in
'At low concentrations of human leucocyte pyrogen, the height of fever in rabbits is
proportional to the amount of supernatant injected (unpublished observations). With higher
concentrations of pyrogen, a logarithmic dose-response curve results (9, 10) and small changes
in the amount of pyrogen cannot be detected,
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FIG. 1. Assay of endogenous pyrogen release from normal or salicylate-treated leucocytes.
Average maximum height of fever + SEM in nine rabbits after injection of supernatants from
18-hr incubations of human blood leucocytes with heat-killed staphylococci ( -) or leuco-
cytes pre-incubated for 1 hr with 40 mg% Na salicylate plus heat-killed staphylococci
(A-.i). One dose in different exp2riments was derived from 9.5-14.0 x 10 leucocytes (see
text for details).
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FIG. 2. Effect of salicylate on febrile responses in rabbits. Average fevers in a group
of five rabbits after injection of a preparation of rabbit endogenous pyrogen (EP). A:
1 ml EP, B: 0.5 ml EP injected on Day 1; C: 1 ml EP injected on Day 5, 1-2 hr after
intraperitoneal Na salicylate 250 mg/kg; D: 1 ml EP injected on Day 7. SEM of the
peak responses is shown.
Fig. 2, curves A and B. Five days later, each rabbit received 250 mg/kg sodium
salicylate by intraperitoneal infusion. Temperatures were then recorded, and 1 or
2 hr later, each rabbit was injected intravenously with a second 1-ml aliquot of
the pyrogenic supernatant. As shown in Fig. 2, C, this injection produced only
half as much fever as did the first (Curve A). To insure that the test solution
had not lost its pyrogenicity, a third 1-ml aliquot was injected two days later. Al-
though the stored material was slightly less pyrogenic than the sample tested ini-
tially (Fig. 2, Curves D and A), it clearly produced more fever than the preceding
injection which followed salicylate treatment (Fig. 2, C). Salicylate thus interfered
in vivo with the pyrogenic action ofpre-formed endogenous pyrogen.
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DISCUSSION
The experiments reported in Tables 1 and 2 indicate that incubation of human
blood leucocytes in vitro with a high concentration of salicylate does not alter their
capacity to release endogenous pyrogen after stimulation by endotoxin or phagocy-
tosis. The experiments by others (1, 11) in which salicylate appeared to suppress
leucocyte pyrogen production differed in several respects from ours. First, rabbit
blood or exudate cells were used, rather than human blood leucocytes. Differences
in the effects of activators and inhibitors on pyrogen production by cells of different
species have been noted (8, 12), and both metabolic (13, 14) and pyrogen-releas-
ing (15, 16) properties of exudate and blood cells differ. Second, blood cells in
one study (1) were incubated with endotoxin in phosphate-buffered saline without
serum or Ca2+. The activation of leucocytes and the induction of pyrogen produc-
tion may differ under these circumstances. In preliminary studies (not reported),
pre-incubation of leucocytes with salicylate in a serum-buffer medium appeared
to augment rather than inhibit the action of endotoxin on leucocyte pyrogen re-
lease. A similar, but smaller, effect occurred when salicylate was added after the
endotoxin (see Table 2). Salicylate may increase the availability of endotoxin for
leucocyte activation by interfering with binding sites for endotoxin on plasma pro-
teins (17). Altered protein binding of other compounds by salicylate has been de-
scribed (18).
Although we do not have a clear explanation for the differences between our
results and those of others (1, 11), our experimental conditions more closely ap-
proximate in vivo clinical situations. Normal human leucocytes were maintained
in a serum-buffer medium and exposed to salicylate both before and after activation
by two inflammatory agents. The lack of effect of the drug under these conditions,
then, seems significant.
In addition to the unimpaired capacity for pyrogen release shown in these
studies, salicylate-treated leucocytes exhibit normal phagocytosis and release of
lysosomal enzymes (19). The stability of isolated human leucocyte lysosomes is
reportedly not enhanced by salicylate (19), in contrast to rat liver lysosomes (20).
Data on anti-inflammatory effects of salicylates do not include evidence for altered
leucocyte function (21).
Recently, it has been proposed that salicylate may act as an antipyretic by in-
hibiting the synthesis and release of certain pyrogenic prostaglandins at sites of
inflammation or in the brain (2, 3). Release of pyrogenic prostaglandins from rab-
bit exudate leucocytes in vitro after phagocytosis has been reported (22), although
the effect of salicylate on this process was not examined. Our studies did not detect
any reduction in the release of pyrogenic substances from salicylate-treated leuco-
cytes. Thus, they do not support the hypothesis that salicylate suppresses fever
by inhibiting prostaglandin release from leucocytes at peripheral sites of
inflammation.
Our experiments confirmed the findings of some investigators (5, 10), but not
another (1), that after administration of parenteral salicylate, rabbits have less
febrile response to injection of preformed endogenous pyrogen. This salicylate
effect, although definite, is small, and its demonstration may require careful atten-
tion to accurate assay techniques. Also, when salicylate is given after the onset
of experimental (6) or clinical fever, rather than before, as in this model, its anti-
pyretic effect is pronounced.
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Our findings, then, do not support the theory that the antipyretic action of salicy-
late results from peripheral effects on release of pyrogen from blood leucocytes.
They do provide support for the concept that the action of salicylate on fever is
primarily a central one.
Note added in proof: Other work indicating lack of effect of salicylate on pro-
gen release from cells of other species has recently been published (23-25).
REFERENCES
1. Gander, G. W., Chaffee, J., and Goodale, F. Proc. Soc. Exp. Biol. Med. 126, 205
(1967).
2. Vane, J. R. Natuire (London) New Biol. 232, 17 (1971).
3. Collier, H. 0. J. Nature 232, 17 (1971).
4. Alder, R. D., Rawlins, M., Rosendorff, C., and Cranston, W. I. Clin. Sci. 37, 91 (1969).
5. Cranston, W. I., Luff, R. H., Rawlins, M. D., and Rosendorff, C. J. Physiol. 208,
251 (1970).
6. Rawlins, M. D., Rosendorff, C., and Cranston, W. L. In "Pyrogens and Fever" (Ciba
Foundation Symposium) (G. E. W. Wolstenholme and J. Birch, eds.), p. 175, Churchill
Livingstone, London, 1971.
7. Malawista, S. E. and Bodel, P. J. Clin. Invest. 46, 786 (1967).
8. Dillard, G. M. and Bodel, P. J. Clin. Invest. 49, 2418 (1970).
9. Root, R. K., Nordlund, J. J., and Wolff, S. M. J. Lab. Clin. Med. 75, 679 (1970).
10. Cranston, W. I., Rawlins, W. I., Luff, R. H., and Duff, G. W. In "Pyrogens and Fever"
(Ciba Foundation Symposium) (G. E. W. Wolstenholme and J. Birch, eds.), p.
155, Churchill Livingstone, London, 1971.
11. Grundman, J. W. Ph. D. Thesis, University of Oxford, 1969.
12. Bodel, P., and Dillard, G. M. J. Clin. Invest. 47, 107 (1968).
13. Hartman, J. D. and Reidenberg, M. J. Appl. Physiol. 12, 477 (1958).
14. Bodel, P. T. and Hollingsworth, J. W. J. Clin. Invest. 45, 580 (1966).
15. Kaiser, H. K. and Wood, W. B. J. Exp. Med. 115, 27 (1962).
16. Bodel, P. T. and Hollingsworth, J. W. Brit. J. Exp. Pathol. 49, 11 (1968).
17. Rudbach, J. A., Anacker, R. L., Haskins, W. T., Johnson, A. G., Wilner, K. C., and
Ribi, E. Ann. N.Y. Acad. Sci. 133, 629 (1966).
18. Osorio, C. In "Salicylates (an international Symposium)" (A. St. J. Dixon, M. J. H.
Smith, B. K. Martin, and P. H. N. Wood, eds.), p. 82. Little, Brown, Boston, 1963.
19. Wright, D. G., Thesis for M.D. Degree, Yale University School of Medicine, 1971.
20. Miller, W. S., and Smith, J. G., Jr. Proc. Soc. Exp. Biol. Med. 122, 634 (1966).
21. Dixon, A. St. J., Martin, B. K., Smith, M. J. H., and Wood, P. H. N., eds. "Salicylates
(an international Symposium)." Little, Brown, Boston, 1962.
22. Higgs, G. A. and Youlten, L. J. ;F. (Abstr.) Brit. J. Pharmacol., p. 330 (1972).
23. Hoo, S. L., Lin, M. T., Wei, R. D., Chai, C. Y., and Wang, S. C. Proc. Soc. Exp.
Biol. Med. 139, 1155 (1972).
24. van Miert, A. S. J. P. A. M., van Essen, J. A., and Tromp, G. A. Arch. Int. Pharmacol.
Ther. 197, 388 (1972).
25. Clark, Wesley G., and Moyer, S. G. J. Pharmacol. Exp. Ther. 181, 183 (1972).